|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
|
16261165 |
2006 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma.
|
12697836 |
2003 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma.
|
12697836 |
2003 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
HIF-1alpha protein expression was analyzed in tumor tissue from 92 patients with RCC.
|
15709180 |
2005 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF-1alpha may therefore represent an important target molecule for RCC therapy; however, HIF-2alpha should be targeted in HIF-1alpha defective renal cancer cells.
|
16920734 |
2007 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity.
|
17482131 |
2007 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypoxia-inducible factor 1α has been shown to play a central role in RCC tumorigenesis by acting as a transcription factor.
|
21275466 |
2011 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HIF-1α C1772T TT genotype and HIF-1α G1790A AA genotype were associated with RCC susceptibility.
|
30539853 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF-1 and total HIF pathway activation scores were decreased with higher ascorbate in pRCC tumors (Spearman <i>r</i> = -0.38, <i>p</i> < 0.05 and <i>r</i> = -0.35, <i>p</i> < 0.05).This was not evident for ccRCC tumors.
|
30555801 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HIF-1α expression was linked to shorter OS in the digestive tract, epithelial ovarian, breast, non-small cell lung, and clear cell renal cell carcinomas.
|
31579115 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AA genotype of HIF1α 1790G/A was positively associated with RCC risk in overall populations and Caucasians.
|
31419966 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abnormal accumulation of c-Myc is able to induce excessive proliferation of normal cells. von Hippel-Lindau protein(pVHL) is a key regulator of hypoxia-inducible factor 1α(HIF1α), thus accumulation and hyperactivation of HIF1α is the most prominent feature of VHL-mutated renal cell carcinoma.
|
22286234 |
2012 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although 24% of Xp11 translocation RCC expressed HIF-1alpha (like CCRCC), unlike CCRCC CA IX expression was characteristically only focal (mean 6% cell labeling) in Xp11 translocation RCC.
|
20679884 |
2010 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Carbonic anhydrase 9 (CA9), which is induced by hypoxia-inducible factor 1 (HIF1) in response to hypoxia, is overexpressed in many types of cancer including renal cell carcinoma (RCC).
|
28851650 |
2017 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell culture metabolomics analysis was utilized to determined effect of VHL and HIF-1α or HIF-2α on metabolism of renal cell carcinomas (RCC).
|
26620126 |
2016 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Collectively, HIF-1alpha activates hTERT and telomerase expression in both RCC and glioma cells, and HIF-2alpha enhances hTERT expression in RCC cells, whereas it represses the hTERT transcription in glioma cells.
|
17699105 |
2007 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, we propose that concurrent activation of p53 and HIF1α may effectively result in cancer-cell apoptosis, and that combined MDM2 antagonists and mTOR inhibitors may be useful in RCC therapy.
|
26937175 |
2016 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Destruction of HIF-1alpha by p53 was corroborated in the present study by using pVHL-deficient RCC4 (renal carcinoma) cells, supporting the notion of a pVHL-independent degradation process.
|
14992692 |
2004 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
|
15217953 |
2004 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.
|
12781449 |
2003 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.
|
27507852 |
2016 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, hepaCAM re-expression significantly decreased glycolytic metabolism in RCC cell lines, and reduced HIF-1α, IKKβ, and P65 expression.
|
30528714 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.
|
19061835 |
2008 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, quantitative analyses of VEGF production and its correlation with VHL mutations and HIF-1 alpha expression in authentic tissues from patients with RCC are lacking.
|
12853836 |
2003 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In renal carcinoma, a natural antisense of HIF-1alpha transcript (aHIF) that is complementary to the 3'untranslated region of HIF-1alpha mRNA has been described.
|
12459261 |
2002 |